RET and non-small cell lung carcinoma: RET-selective TKIs (selpercatinib and pralsetinib) have revolutionized the landscape of RET+ advanced NSCLC treatment thanks to their efficacy and safety profiles, and currently represent the standard of care for both naïve patients and patients that have not received a selective RET-TKI in the first-line setting.